Immunotherapy

A Decade Later, Patient Receiving CAR T-Cell Therapy “Cured of Cancer”

February 2022 has been an important month in…
Read Article

CAR T-Cell Therapies – Now Targeting Solid Tumors

Most in oncology drug development are aware of…
Read Article

Cancer Vaccines – Promising Research Gets Closer to Reality

Vaccines are at the top of everyone’s mind…
Read Article

Preparing for Your Phase I Oncology Study

The phase 1 study is the gateway between…
Read Article

Managing the Side Effects in a CAR T-cell Therapy Study

CAR T-cell therapy, together with checkpoint inhibition, has…
Read Article

Common Causes of Delays in Immuno-Oncology Studies

It’s common for “standard” oncology studies to encounter…
Read Article

Challenges with Checkpoint Inhibitors in the Clinic

Checkpoint inhibitors, including those targeting PD-1 and PD-L1,…
Read Article

Bispecific Antibody Treatments, AML & Immunotherapy Treatments

With the ASH 2018 annual meeting right around…
Read Article

Guidelines for the Evaluation of Immune Therapy Activity

In a previous article, we discussed therapies that…
Read Article